“Maintenance of Clinical Response With Continued Risankizumab Treatment for Moderate-to-Severe Psoriasis Through 304 Weeks: Interim Analysis of the LIMMitless Open-Label Extension Study” (2023) SKIN The Journal of Cutaneous Medicine, 7(6), p. s258. doi:10.25251/skin.7.supp.258.